Related Experiment Video
Updated: Aug 9, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Ranolazine: focusing on angina pectoris
1Department of Medicine, Divisions of Cardiology, Nutrition and Preventive Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073, USA. pmc975@yahoo.com
Abstract:
Chronic stable angina is common and is a difficult-to-manage problem when patients begin to fail conventional therapy especially when maximal revascularization has been provided. The most promising agent in development is ranolazine, a late sodium channel inhibitor and partial fatty oxidation inhibitor which has unique and desirable anti-ischemic and electrophysiologic properties. This agent is likely to become standard therapy for chronic stable angina and may play a future role in the management of acute coronary syndromes.
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Angina IV: Management
Angina V: Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Angina III: Clinical Manifestations and Assessment

